When does Mounjaro’s patent expire?
Mounjaro (tirzepatide) is protected by a network of patents and patent-term extensions rather than a single “expiration date.” The exact expiry depends on the jurisdiction (for example, the U.S. vs. Europe) and on how each patent is challenged, licensed, or extended.
What’s the likely U.S. patent expiry window for tirzepatide?
In the U.S., courts and filings associated with Mounjaro’s biosimilar competition have pointed to patent protection extending into the late 2020s, with some exclusivity/patent activity continuing past 2028. Specific dates can vary by patent family and whether you’re asking about (1) patent expiry versus (2) regulatory exclusivities (which can extend beyond the last patent).
Why are there multiple “expiration” dates (patents vs exclusivity)?
People often see different dates because “when it expires” can mean different protections:
- Patent expiry for specific claims covering the drug and/or its manufacturing/formulation.
- Regulatory exclusivities (separate from patents) that can delay generic/biosimilar entry even after certain patents end.
- Country-by-country differences, since patent terms and extensions aren’t identical across markets.
Do biosimilars or generics wait for the last patent?
For biologics like tirzepatide, biosimilars typically can enter only after the relevant patent and exclusivity barriers clear. Even if one patent expires, remaining patents (or exclusivity periods) can still block commercial launch.
How can you check the exact expiry date for your country?
The most accurate way is to look up the specific tirzepatide (Mounjaro) patent list in the country of interest and identify:
- the patent numbers and claimed subject matter,
- any patent-term adjustments/extensions,
- whether any patents were invalidated or narrowed through litigation,
- and which regulatory exclusivities apply.
If you tell me which country you care about (U.S., UK, EU, Canada, etc.), I can narrow the answer to the relevant jurisdiction’s patent/exclusivity timeline.
Sources
No sources were provided in the prompt.